Efficacy and safety of rebamipide for the treatment of dry mouth symptoms in patients with Sjögren's syndrome: A double-blind placebo-controlled multicenter trial

Modern Rheumatology

Volumn 19, Issue 2, 2009, Pages 114-124

  Sugai, Susumu ^a,m   Takahashi, Hiroki ^b   Ohta, Shuji ^c   Nishinarita, Makoto ^d   Takei, Masami ^e   Sawada, Shigemasa ^e,f   Yamaji, Ken ^g   Oka, Hiroshi ^h   Umehara, Hisanori ^a   Koni, Ichiro ⁱ   Sugiyama, Eiji ^j   Nishiyama, Susumu ^k   Kawakami, Atsushi ^l  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Taga General Hospital   (Japan)

^d Nishinarita Clinic Office   (Japan)

^e NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f NIHON UNIVERSITY   (Japan)

^g JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^j UNIVERSITY OF TOYAMA   (Japan)

^k Kurashiki Medical Center   (Japan)

^l NAGASAKI UNIVERSITY   (Japan)

^m Nagasaki University ^*  (Japan)

more..

Author keywords

Dry mouth; Rebamipide; Saxon test; Sj gren's syndrome

Indexed keywords

PLACEBO; REBAMIPIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENITAL PRURITUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALIVATION; SIDE EFFECT; SJOEGREN SYNDROME; SYMPTOMATOLOGY; TREATMENT DURATION; XEROSTOMIA;

AGED; ALANINE; ANTI-INFLAMMATORY AGENTS; DOUBLE-BLIND METHOD; EATING; FEMALE; HUMANS; MALE; MIDDLE AGED; MOUTH; PROSTAGLANDINS; QUINOLONES; SALIVA; SJOGREN'S SYNDROME; SLEEP; TREATMENT OUTCOME; XEROSTOMIA;

EID: 64449084197     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-008-0141-1     Document Type: Article

References (24)

1. Moutsopoulos HM. Sjögren's syndrome: Autoimmune epithelitis. Clin Immunol Immunopathol. 1994;72:162-5.
2. Fox RI. Sjögren's syndrome. Lancet. 2005;366:321-31.
3. Ramos-Casals M, Brito-Zerón P. New approaches in Sjögren's syndrome therapy. Expert Rev Clin Immunol. 2007;3:195-204.
4. Thanou-Stavraki A, James JA. Primary Sjogren's syndrome: Current and prospective therapies. Semin Arthritis Rheum. 2008;37:273-92.
5. Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 2007;57:310-7.
6. Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A, et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum. 2007;56:1464-77.
7. Nakayamada S, Saito K, Nakatsuka K, Nakano K, Tokunaga M, Sawamukai N, et al. Efficacy of mizoribine treatment in patients with Sjögren's syndrome: An open pilot trial. Mod Rheumatol. 2003;13:339-45.
8. Nakayamada S, Saito K, Umehara H, Ogawa N, Sumida T, Ito S, et al. Efficacy and safety of mizoribine for the treatment of Sjögren's syndrome: A multicenter open-label clinical trial. Mod Rheumatol. 2007;17:464-9.
9. Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A. Rebamipide: Overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 1998;43:5S-13S.
10. Arakawa T, Higuchi K, Fujiwara Y, Watanabe T, Tominaga K, Sasaki E, et al. 15th anniversary of rebamipide: Looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005;50:S3-S11.
11. Kohashi M, Ishimaru N, Arakai R, Hayashi Y. Effective treatment with oral administration of rebamipide in a mouse model of Sjögren's syndrome. Arthritis Rheum. 2008;58:389-400.
12. Oka H, Nakano H, Kimata T, Matsuda T, Ozaki S. Effect of rebamipide for the treatment of xerostomia in patients with Sjögren's syndrome. Progr Med. 2004;24:205-10.
13. Kohler PF, Winter ME. A quantitative test for xerostomia. The Saxon test, an oral equivalent of the Schirmer test. Arthritis Rheum. 1985;28:1128-32.
14. Strong B, Farley W, Stern ME, Pflugfelder SC. Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca. Cornea. 2005;24:80-5.
15. Cummins MJ, Papas A, Kammer GM, Fox PC. Treatment of primary Sjögren's syndrome with low-dose human interferon alfa administered by the oromucosal route: Combined phase III results. Arthritis Rheum. 2003;49:585-93.
16. Smith JK, Siddiqui AA, Modica LA, Dykes R, Simmons C, Schmidt J, et al. Interferon-alpha upregulates gene expression of aquaporin-5 in human parotid glands. J Interferon Cytokine Res. 1999;19:929-35.
17. Fox RI, Chan E, Benton L, Fong S, Friedlaender M, Howell FV. Treatment of primary Sjögren's syndrome with hydroxychloroquine. Am J Med. 1988;85:62-7.
18. Tishler M, Yaron I, Shirazi I, Yaron M. Hydroxychloroquine treatment for primary Sjögren's syndrome: Its effect on salivary and serum inflammatory markers. Ann Rheum Dis. 1999;58:253-6.
19. Miyawaki S, Nishiyama S, Matoba K. Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjögren's syndrome. Intern Med. 1999;38:938-43.
20. Zandbelt MM, van den Hoogen FH, de Wilde PC, van den Berg PJ, Schneider HG, van de Putte LB. Reversibility of histological and immunohistological abnormalities in sublabial salivary gland biopsy specimens following treatment with corticosteroids in Sjögren's syndrome. Ann Rheum Dis. 2001;60:511-3.
21. Aihara M, Imagawa K, Funakoshi Y, Ohmoto Y, Kikuchi M. Effects of rebamipide on production of several cytokines by human peripheral blood mononuclear cells. Dig Dis Sci. 1998;43:160S-6S.
22. Yoshikawa T, Naito Y, Tanigawa T, Kondo M. Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance. Arzneimittelforschung. 1993;43:363-6.
23. Urashima H, Okamoto T, Takeji Y, Shinohara H, Fujisawa S. Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model. Cornea. 2004;23:613-9.
24. Ríos JD, Shatos M, Urashima H, Tran H, Dartt DA. OPC-12759 increases proliferation of cultured rat conjunctival goblet cells. Cornea. 2006;25:573-81.